April 2025 – Conquest Research, LLC ("Conquest"), a portfolio company of Reynolda Equity Partners ("Reynolda"), has acquired Sana Research, LLC (“Sana”).

Headquartered in Winter Park, FL, Conquest is a clinical trial site network with expertise in neurology, orthopedics, rheumatology, pain, cardiometabolics, internal medicine, and other critical therapeutic areas. Conquest's Founder & CEO Mark Daley and CMO Dr. Anand Patel lead a team of experienced Principal Investigators serving global pharmaceutical companies, CROs and biotechs, with a track record of growth across multiple therapeutic indications.

Based in Arlington, VA, Sana focuses on trials within the areas of neurologic, cardiovascular, and metabolic diseases and is dedicated to advancing medical research and improving patient outcomes. Founder and Principal Investigator Dr. Henry Tran aligns with Conquest’s standards of excellence, and Sana bolsters Conquest’s therapeutic coverage and expands its footprint into the Washington, DC market.

The Sana acquisition marks an important milestone in Conquest’s expansion. Conquest is building a strategic multi-state network of select sites in order to provide best-in-class service to its pharmaceutical customer base.

“We’re thrilled to welcome Sana Research into the Conquest Research family,” said Mark Daley. “This acquisition represents a significant milestone in our strategic expansion into the DMV region, aligning perfectly with our mission to advance clinical research in neurodegenerative and cardiometabolic diseases. Sana’s exceptional team, geographic presence, and shared therapeutic focus strengthen our ability to deliver exceptional services to our pharmaceutical partners and bring safer, more effective treatment options to the communities we serve.”

“Conquest operates within a compelling market in which Reynolda has achieved significant previous success,” added Ken Clark, a Partner at Reynolda. “Reynolda enthusiastically supports management's plan to grow the platform via organic expansion, establishment of new locations and selective M&A.”

Conquest continues to evaluate acquisition opportunities to add select sites with specific therapeutic expertise and geographic coverage to the expanding network.